Polycystic Liver Disease: The benefits of targeting cAMP

Documenti analoghi

• Therapeutic Targets in Polycystic Liver Disease
  di: Masyuk, Tatyana V., et al.
  Pubblicazione: (2017)
• Polycystic Liver Disease: the interplay of genes causative for hepatic and renal cystogenesis
  di: Masyuk, Tatyana V, et al.
  Pubblicazione: (2018)
• TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases via cAMP/Gα(s) signaling
  di: Masyuk, Tatyana V, et al.
  Pubblicazione: (2017)
• The cAMP Effectors Epac and PKA are Involved in the Hepatic Cystogenesis of an Animal Model of ARPKD
  di: Banales, Jesús M., et al.
  Pubblicazione: (2009)
• Cholangiocyte Autophagy Contributes to Hepatic Cystogenesis in Polycystic Liver Disease and Represents a Potential Therapeutic Target
  di: Masyuk, Anatoliy I., et al.
  Pubblicazione: (2018)